Somatostatin
Somatostatin-14, SST-14, SRIF, Somatotropin release-inhibiting factor, Growth hormone-inhibiting hormone, Somatostatin-28
Somatostatin is the body's own universal inhibitory hormone, a 14-amino-acid cyclic peptide discovered in 1973 as the hypothalamic factor that blocks growth hormone release. It restrains secretion across the pituitary, pancreas and gut. As a medicine it is barely usable, because it survives only minutes in the bloodstream, which is why octreotide, lanreotide and pasireotide exist.
Mechanism
Somatostatin is produced by hypothalamic periventricular neurones, by pancreatic islet delta cells, by gastric and intestinal D cells, and by scattered neurones throughout the central and peripheral nervous system. It acts on five G-protein-coupled receptors, SSTR1 to SSTR5, all coupling through Gi/Go. Receptor activation inhibits adenylyl cyclase and lowers cyclic AMP, opens inwardly rectifying and delayed-rectifier potassium channels to hyperpolarise the cell, closes L-type and N-type voltage-gated calcium channels, and activates protein tyrosine phosphatases including SHP-1 and SHP-2. The convergent result is suppression of regulated exocytosis. Unlike the synthetic analogues, native somatostatin binds all five subtypes with comparably high affinity, which is why its physiological effects are so broad and why a synthetic version would be a poor drug even if it were stable.
The range of what it inhibits is remarkable: growth hormone and thyrotropin from the anterior pituitary; insulin, glucagon and pancreatic polypeptide from the islets; gastrin, secretin, cholecystokinin, motilin, vasoactive intestinal peptide, gastric inhibitory polypeptide and serotonin from the gut; gastric acid from parietal cells; and pancreatic exocrine bicarbonate and enzyme output. It also reduces splanchnic blood flow and portal venous pressure, slows gastrointestinal motility and gallbladder contraction, and reduces intestinal fluid secretion and absorption. Within the central nervous system it acts as a neuromodulator, and somatostatin-expressing interneurones are a major inhibitory population in the cortex and hippocampus, with SSTR receptors also implicated in cognition and in the pathology of Alzheimer's disease, where somatostatin levels fall. Somatostatin-28 is relatively SSTR5-preferring and is the dominant circulating form in the gut, whereas somatostatin-14 predominates in neural tissue.
What the research shows
Somatostatin's scientific standing and its therapeutic standing are very different things, and conflating the two is the most common error in how this peptide is described. The physiology is settled: since Brazeau and colleagues isolated it in 1973, somatostatin has been established as the principal inhibitory regulator of the growth hormone axis, of islet hormone secretion, of gastric acid and of gut peptide release, acting through five well-characterised receptor subtypes whose distribution and signalling are mapped in detail. Radiolabelled somatostatin analogues are the basis of somatostatin receptor imaging and of peptide receptor radionuclide therapy in neuroendocrine tumours, which is a genuine and important clinical translation of the biology.
As a therapeutic agent in its own right, native somatostatin has largely failed, and for a straightforward reason. A one-to-three-minute half-life demands continuous intravenous infusion, which restricts it to hospital use in acute settings. Where it has been tested at scale, in acute variceal haemorrhage, the Cochrane meta-analysis across 21 trials and 2,588 patients found no mortality benefit and only marginal transfusion sparing of doubtful clinical value, though it did reduce failure of initial haemostasis. A separate 2021 meta-analysis of 21 randomised trials found the somatostatin family broadly equivalent to terlipressin and vasopressin on efficacy while causing significantly fewer adverse events, which is a modest point in its favour. Trials in acute pancreatitis and in pancreatic fistula have been small and inconsistent. Its indiscriminate binding across all five receptor subtypes also produces unwanted suppression of insulin and glucagon and rebound hypersecretion when an infusion stops. Every clinically successful drug in this class has been an engineered analogue that trades receptor breadth for stability and selectivity. Somatostatin-based products sold to consumers as peptides have no evidence base whatsoever for oral or subcutaneous self-administration, and the pharmacokinetics make such use implausible on its face.
Evidence assessment
Mixed evidence
The physiology of somatostatin is definitively established and is not in question; this tier deliberately reflects the therapeutic evidence, as it should. As a medicine, native somatostatin has been tested mainly in acute variceal bleeding and in pancreatic conditions. The Cochrane review of 21 trials and 2,588 patients found no mortality reduction and doubted whether the transfusion sparing was worthwhile, although it did find a significant reduction in failure of initial haemostasis. A separate meta-analysis of 21 randomised trials found the somatostatin family broadly equivalent to the vasopressin family on efficacy outcomes with fewer adverse events. Native somatostatin has no approval in the United States or United Kingdom. Substantial human trial data with conflicting and generally unimpressive results is the definition of mixed.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone Preclinical only
The discovery paper. A 14-residue peptide isolated from sheep hypothalamus inhibited growth hormone secretion at very low concentrations both in cell culture and in vivo, and the synthetic replicate was biologically active. This work, from the Guillemin laboratory, defined the entire somatostatin field and underpins every analogue that followed.
Somatostatin analogues for acute bleeding oesophageal varices Preclinical only
A largely negative result. Mortality was not significantly reduced (relative risk 0.97, 95% CI 0.75 to 1.25 in trials at low risk of bias). Transfusion requirement fell by 0.7 units in the low-risk-of-bias trials, which the reviewers described as about half a unit saved per patient and doubted was worthwhile. Rebleeding was not significantly reduced in the better trials. Against that, failure of initial haemostasis was significantly reduced (RR 0.68, 0.54 to 0.87). The reviewers called for a large placebo-controlled trial enrolling thousands of patients before mortality effects could be ruled out.
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group Preclinical only
Included here as context for the somatostatin receptor pathway rather than for the native peptide, and that distinction should be kept firmly in view. Time to tumour progression was 14.3 versus 6.0 months. It demonstrates that the somatostatin receptor system is a genuine antiproliferative target, but only when engaged by a molecule stable enough to occupy the receptor for weeks rather than minutes.
Safety
Native somatostatin given by infusion causes nausea, abdominal cramping, diarrhoea and flushing. Because it suppresses insulin and glucagon simultaneously and non-selectively, glucose can move in either direction, with early hypoglycaemia followed by hyperglycaemia described during infusions. Bradycardia and transient conduction disturbances occur. The most clinically distinctive problem is rebound: abruptly stopping an infusion can produce a surge of growth hormone, gastrin and gastric acid, so tapering is standard where the peptide is used.
There is a separate and more important safety point for a peptide education library. Somatostatin-14 sold as a research chemical is not a pharmaceutical product and carries no marketing authorisation in the United States or United Kingdom. It has never been characterised for subcutaneous self-administration, no dosing evidence exists for that route, purity and sterility are unverified, and its two-minute half-life makes any non-infusion route pharmacologically pointless. Anyone considering somatostatin receptor pharmacology for a genuine medical indication should be under specialist care with a licensed analogue.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Not licensed by the MHRA. Native somatostatin infusion has been used historically in some continental European countries for acute variceal haemorrhage and pancreatic fistula, but UK practice uses terlipressin or octreotide instead. Sold in the UK only as a research chemical and reference standard, not for human use. |
| United States | Not approved as a medicine in the United States. Native somatostatin-14 is available only as a laboratory reagent and pharmacopoeial reference standard. It is not a controlled substance, but it has no legal route to human therapeutic use in the US, and marketing it for human consumption would be unlawful. |
| WADA (sport) | Not prohibited on the current Prohibited List. Somatostatin suppresses growth hormone release rather than stimulating it, placing it outside category S2.2. Its pharmacology is the inverse of the growth hormone secretagogues that are banned. |
Questions
Because native somatostatin lasts one to three minutes in the bloodstream, so it can only be given as a continuous intravenous drip. Octreotide, lanreotide and pasireotide are engineered to resist the enzymes that destroy it, extending the half-life from minutes to hours or, in depot form, weeks. They are also receptor-selective, which reduces unwanted suppression of insulin and glucagon. Stability and selectivity are the entire reason the analogues exist.
Not completely, but it is the dominant physiological brake. Growth hormone release reflects the balance between growth hormone-releasing hormone, ghrelin acting at the GHS-R1a receptor, and somatostatin acting as the inhibitor. The characteristic pulsatile pattern of growth hormone secretion arises from rhythmic alternation between somatostatin tone and releasing-hormone drive rather than from any one signal alone.
No. There is no human evidence supporting any anti-ageing use, and the proposition runs against the biology: somatostatin suppresses the growth hormone and IGF-1 axis rather than enhancing it. Its established therapeutic testing has been in acute variceal bleeding and pancreatic conditions, where the Cochrane evidence found no mortality benefit. Claims to the contrary are not supported by the literature.
In several places, which is why its effects are so widespread. Hypothalamic periventricular neurones supply the pituitary portal system, pancreatic islet delta cells regulate neighbouring insulin and glucagon cells, gastric and intestinal D cells control acid and gut peptide secretion, and somatostatin-expressing interneurones form a major inhibitory population in the cortex and hippocampus.